This is a news story, published by Front Page, that relates primarily to Roswell Park Comprehensive Cancer Center news.
For more vaccine development news, you can click here:
more vaccine development newsFor more news from Front Page, you can click here:
more news from Front PageOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
groundbreaking lung cancer immunotherapy drug CIMAvax. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest CIMAvax vaccine news, lung cancer news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
lung cancer vaccineFront Page
•
67% Informative
Researchers at Roswell Park Comprehensive Cancer Center are taking the next steps with a lung cancer vaccine.
The groundbreaking lung cancer immunotherapy drug CIMAvax-EGF is now being studied in the prevention of the disease.
Adults between the ages of 50-79 are eligible to participate in this trial.
VR Score
72
Informative language
75
Neutral language
6
Article tone
formal
Language
English
Language complexity
52
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links